Handel Paratek Pharma - PRTK CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.06 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.030779% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | -0.013666% | ||||||||
Gebyr natten over, tid | 22:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 2.1 |
Åben* | 2.08 |
1-Års Ændring* | -48.89% |
Dagens Spænd* | 2.03 - 2.11 |
52-Ugers Spænd | 1.60-4.25 |
Gennemsnitlig Volumen (10 dage) | 228.13K |
Gennemsnitlig Volumen (3 måneder) | 7.13M |
Market Cap | 117.77M |
P/E-forhold | -100.00K |
Udestående aktier | 55.55M |
Omsætning | 116.51M |
EPS | -1.69 |
Dividend (Udbytte %) | N/A |
Beta | 1.49 |
Næste indtjeningsopgørelse | Mar 13, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Feb 8, 2023 | 2.03 | -0.05 | -2.40% | 2.08 | 2.11 | 2.03 |
Feb 7, 2023 | 2.10 | -0.04 | -1.87% | 2.14 | 2.15 | 2.07 |
Feb 6, 2023 | 2.11 | -0.07 | -3.21% | 2.18 | 2.24 | 2.09 |
Feb 3, 2023 | 2.20 | 0.02 | 0.92% | 2.18 | 2.28 | 2.18 |
Feb 2, 2023 | 2.24 | 0.16 | 7.69% | 2.08 | 2.25 | 2.08 |
Feb 1, 2023 | 2.11 | 0.00 | 0.00% | 2.11 | 2.16 | 2.06 |
Jan 31, 2023 | 2.15 | 0.14 | 6.97% | 2.01 | 2.15 | 2.01 |
Jan 30, 2023 | 2.03 | 0.04 | 2.01% | 1.99 | 2.10 | 1.98 |
Jan 27, 2023 | 2.05 | 0.00 | 0.00% | 2.05 | 2.11 | 2.04 |
Jan 26, 2023 | 2.08 | 0.09 | 4.52% | 1.99 | 2.08 | 1.96 |
Jan 25, 2023 | 2.03 | -0.03 | -1.46% | 2.06 | 2.06 | 1.87 |
Jan 24, 2023 | 2.05 | -0.09 | -4.21% | 2.14 | 2.18 | 2.05 |
Jan 23, 2023 | 2.15 | 0.05 | 2.38% | 2.10 | 2.21 | 2.09 |
Jan 20, 2023 | 2.09 | 0.06 | 2.96% | 2.03 | 2.10 | 1.97 |
Jan 19, 2023 | 2.01 | -0.07 | -3.37% | 2.08 | 2.14 | 2.01 |
Jan 18, 2023 | 2.10 | -0.30 | -12.50% | 2.40 | 2.40 | 2.06 |
Jan 17, 2023 | 2.30 | -0.06 | -2.54% | 2.36 | 2.38 | 2.29 |
Jan 13, 2023 | 2.37 | 0.05 | 2.16% | 2.32 | 2.46 | 2.30 |
Jan 12, 2023 | 2.39 | 0.14 | 6.22% | 2.25 | 2.40 | 2.23 |
Jan 11, 2023 | 2.27 | -0.01 | -0.44% | 2.28 | 2.28 | 2.21 |
Paratek Pharma Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total omsætning | 0.029 | 12.616 | 17.117 | 16.544 | 46.924 | 130.162 |
Omsætning | 0.029 | 12.616 | 17.117 | 16.544 | 46.924 | 130.162 |
Totale Driftsudgifter | 109.515 | 97.196 | 121.202 | 132.173 | 124.796 | 171.292 |
Salgs/Generelle/Admin. Udgifter, Total | 26.4 | 36.965 | 63.658 | 89.135 | 89.355 | 119.004 |
Forskning & Udvikling | 83.46 | 60.072 | 57.508 | 39.554 | 23.922 | 30.353 |
Renteudgift (Indkomst) - Netto Drift | -0.345 | -0.584 | -0.071 | 0 | ||
Usædvanlig Udgift (Indkomst) | 0 | 0.743 | 0.107 | 0 | 2.368 | 0 |
Driftsindtægter | -109.486 | -84.58 | -104.085 | -115.629 | -77.872 | -41.13 |
Renteindkomst (Udgift), Netto Ikke-Drift | -2.154 | -3.702 | -7.725 | -12.829 | -18.725 | -17.342 |
Andre, Netto | 0.004 | -0.034 | -0.044 | -0.031 | 0.056 | -0.012 |
Netto Indkomst Før Skat | -111.636 | -88.316 | -111.854 | -128.489 | -96.541 | -58.484 |
Netto Indkomst Efter Skat | -111.636 | -89.069 | -112.356 | -128.79 | -96.541 | -59.084 |
Netto Indkomst Før Ekstra Ting | -111.636 | -89.069 | -112.356 | -128.79 | -96.541 | -59.084 |
Netto Indkomst | -111.636 | -89.069 | -112.356 | -128.79 | -96.541 | -59.084 |
Total Adjustments to Net Income | 0 | |||||
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -111.636 | -89.069 | -112.356 | -128.79 | -96.541 | -59.084 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -111.636 | -89.069 | -112.356 | -128.79 | -96.541 | -59.084 |
Fortyndet Netto Indkomst | -111.636 | -89.069 | -112.356 | -128.79 | -96.541 | -59.084 |
Fortyndet Vægtet Gennemsnit Aktier | 20.2531 | 26.8272 | 31.5135 | 32.7919 | 44.1748 | 48.4155 |
Fortyndet EPS Uden Ekstraordinære Ting | -5.51205 | -3.32009 | -3.56533 | -3.92749 | -2.18543 | -1.22035 |
Fortyndet Normaliseret EPS | -5.51205 | -3.30209 | -3.56313 | -3.92749 | -2.13183 | -1.22035 |
Kost af omsætning, Total | 3.484 | 8.651 | 21.535 | |||
Bruttofortjeneste | 13.06 | 38.273 | 108.627 | |||
Depreciation / Amortization | 0.5 | 0.4 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total omsætning | 16.427 | 57.492 | 24.447 | 31.797 | 24.861 |
Omsætning | 16.427 | 57.492 | 24.447 | 31.797 | 24.861 |
Kost af omsætning, Total | 2.751 | 9.778 | 4.289 | 4.718 | 3.494 |
Bruttofortjeneste | 13.676 | 47.714 | 20.158 | 27.079 | 21.367 |
Totale Driftsudgifter | 30.648 | 43.403 | 38.164 | 59.078 | 38.574 |
Salgs/Generelle/Admin. Udgifter, Total | 22.359 | 27.106 | 25.955 | 43.984 | 27.602 |
Forskning & Udvikling | 5.538 | 6.519 | 7.92 | 10.376 | 7.478 |
Driftsindtægter | -14.221 | 14.089 | -13.717 | -27.281 | -13.713 |
Renteindkomst (Udgift), Netto Ikke-Drift | -4.282 | -4.333 | -4.342 | -4.384 | -4.372 |
Andre, Netto | 0.157 | -0.039 | -0.143 | 0.012 | 0.175 |
Netto Indkomst Før Skat | -18.346 | 9.717 | -18.202 | -31.653 | -17.91 |
Netto Indkomst Efter Skat | -18.346 | 9.717 | -18.202 | -32.253 | -17.91 |
Netto Indkomst Før Ekstra Ting | -18.346 | 9.717 | -18.202 | -32.253 | -17.91 |
Netto Indkomst | -18.346 | 9.717 | -18.202 | -32.253 | -17.91 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -18.346 | 9.717 | -18.202 | -32.253 | -17.91 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -18.346 | 9.717 | -18.202 | -32.253 | -17.91 |
Fortyndet Netto Indkomst | -18.346 | 9.717 | -18.202 | -32.253 | -17.91 |
Fortyndet Vægtet Gennemsnit Aktier | 46.6644 | 48.9457 | 49.214 | 50.6329 | 52.1495 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.39315 | 0.19853 | -0.36985 | -0.637 | -0.34344 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.39315 | 0.19853 | -0.36985 | -0.637 | -0.34344 |
Usædvanlig Udgift (Indkomst) | 0 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totale Nuværende Aktiver | 132.1 | 160.486 | 255.243 | 243.354 | 164.117 | 152.1 |
Likvider og Kortsigtede Investeringer | 128.038 | 151.723 | 250.351 | 215.379 | 125.162 | 95.474 |
Likvider & Lignende | 52.962 | 35.416 | 46.987 | 102.302 | 105.157 | 80.367 |
Kortsigtede Investeringer | 75.076 | 116.307 | 203.364 | 113.077 | 20.005 | 15.107 |
Totale Tilgodehavender, Netto | 0.323 | 5.889 | 0.249 | 9.583 | 15.733 | 33.117 |
Accounts Receivable - Trade, Net | 0.323 | 5.889 | 0.249 | 9.583 | 15.733 | 33.117 |
Prepaid Expenses | 2.922 | 2.712 | 4.377 | 6.489 | 7.776 | 12.364 |
Other Current Assets, Total | 0.817 | 0.162 | 0.266 | 0.324 | 0.891 | 0.125 |
Total Assets | 135.732 | 163.698 | 300.192 | 251.079 | 176.853 | 183.869 |
Property/Plant/Equipment, Total - Net | 1.188 | 1.711 | 1.173 | 3.741 | 2.974 | 2.551 |
Property/Plant/Equipment, Total - Gross | 2.009 | 2.925 | 2.985 | 6.077 | 5.761 | 4.814 |
Accumulated Depreciation, Total | -0.821 | -1.214 | -1.812 | -2.336 | -2.787 | -2.263 |
Goodwill, Net | 0.829 | 0.829 | 0.829 | 0.829 | 0.829 | 0.829 |
Intangibles, Net | 1.015 | 0.142 | 0 | |||
Other Long Term Assets, Total | 0.6 | 0.53 | 0.46 | 3.155 | 8.933 | 28.389 |
Total Current Liabilities | 20.412 | 16.789 | 17.709 | 24.2 | 23.953 | 31.297 |
Accounts Payable | 4.467 | 3.679 | 2.09 | 4.116 | 1.813 | 5.394 |
Accrued Expenses | 15.889 | 13.11 | 15.619 | 17.696 | 21.626 | 24.046 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.056 | 2.388 | 0.514 | 1.857 | ||
Total Liabilities | 64.14 | 81.22 | 252.614 | 290.726 | 279.113 | 311.656 |
Total Long Term Debt | 39.629 | 59.257 | 228.959 | 260.728 | 250.474 | 254.428 |
Long Term Debt | 39.629 | 59.257 | 228.959 | 260.728 | 250.474 | 254.428 |
Other Liabilities, Total | 4.099 | 5.174 | 5.946 | 5.798 | 4.686 | 25.931 |
Total Equity | 71.592 | 82.478 | 47.578 | -39.647 | -102.26 | -127.787 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | |||
Common Stock | 0.023 | 0.028 | 0.032 | 0.04 | 0.046 | 0.052 |
Additional Paid-In Capital | 451.947 | 552.72 | 630.142 | 671.497 | 705.489 | 739.053 |
Retained Earnings (Accumulated Deficit) | -380.362 | -470.112 | -582.468 | -711.258 | -807.799 | -866.883 |
Other Equity, Total | -0.016 | -0.158 | -0.128 | 0.074 | 0.004 | -0.009 |
Total Liabilities & Shareholders’ Equity | 135.732 | 163.698 | 300.192 | 251.079 | 176.853 | 183.869 |
Total Common Shares Outstanding | 23.3586 | 27.941 | 32.2594 | 39.8278 | 46.5166 | 51.7118 |
Long Term Investments | 42.487 | 0 | ||||
Total Inventory | 11.579 | 14.555 | 11.02 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 141.831 | 153.504 | 153.011 | 152.1 | 133.282 |
Likvider og Kortsigtede Investeringer | 103.45 | 75.298 | 110.999 | 95.474 | 79.053 |
Likvider & Lignende | 103.45 | 75.298 | 110.999 | 80.367 | 49.033 |
Kortsigtede Investeringer | 0 | 0 | 0 | 15.107 | 30.02 |
Totale Tilgodehavender, Netto | 18.538 | 60.809 | 22.132 | 33.117 | 28.259 |
Accounts Receivable - Trade, Net | 18.538 | 60.809 | 22.132 | 33.117 | 28.259 |
Total Inventory | 14.207 | 7.954 | 8.824 | 11.02 | 12.732 |
Prepaid Expenses | 5.212 | 9.318 | 10.931 | 12.364 | 12.988 |
Other Current Assets, Total | 0.424 | 0.125 | 0.125 | 0.125 | 0.25 |
Total Assets | 159.277 | 179.588 | 182.348 | 183.869 | 170.157 |
Property/Plant/Equipment, Total - Net | 2.744 | 3.07 | 2.688 | 2.551 | 2.298 |
Goodwill, Net | 0.829 | 0.829 | 0.829 | 0.829 | 0.829 |
Other Long Term Assets, Total | 13.873 | 22.185 | 25.82 | 28.389 | 33.748 |
Total Current Liabilities | 22.957 | 20.977 | 29.15 | 31.297 | 28.837 |
Accounts Payable | 4.045 | 2.59 | 4.991 | 5.394 | 4.697 |
Accrued Expenses | 18.33 | 18.061 | 23.764 | 24.046 | 22.733 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.582 | 0.326 | 0.395 | 1.857 | 1.407 |
Total Liabilities | 278.285 | 278.879 | 287.341 | 311.656 | 310.459 |
Total Long Term Debt | 250.809 | 252.759 | 253.269 | 254.428 | 255.949 |
Long Term Debt | 250.809 | 252.759 | 253.269 | 254.428 | 255.949 |
Other Liabilities, Total | 4.519 | 5.143 | 4.922 | 25.931 | 25.673 |
Total Equity | -119.008 | -99.291 | -104.993 | -127.787 | -140.302 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
Common Stock | 0.047 | 0.048 | 0.05 | 0.052 | 0.053 |
Additional Paid-In Capital | 707.09 | 717.089 | 729.587 | 739.053 | 744.618 |
Retained Earnings (Accumulated Deficit) | -826.145 | -816.428 | -834.63 | -866.883 | -884.793 |
Other Equity, Total | 0 | 0 | 0 | -0.009 | -0.18 |
Total Liabilities & Shareholders’ Equity | 159.277 | 179.588 | 182.348 | 183.869 | 170.157 |
Total Common Shares Outstanding | 46.9072 | 47.9965 | 50.0202 | 51.7118 | 53.0233 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netto indkomst/Startlinje | -111.636 | -89.069 | -112.356 | -128.79 | -96.541 | -59.084 |
Likvider Fra Driftsaktiviteter | -94.098 | -78.574 | -81.179 | -134.045 | -103.424 | -48.273 |
Likvider Fra Driftsaktiviteter | 2.303 | 1.268 | 0.578 | 0.391 | ||
Ikke-Likvide Ting | 10.688 | 17.467 | 27.254 | 16.483 | 12.825 | 18.609 |
Likvid Rente Betalt | 1.582 | 3.705 | 9.31 | 15.96 | 22.703 | 13.144 |
Ændringer i Driftskapital | 4.547 | -8.24 | 3.923 | -21.738 | -20.286 | -8.189 |
Likvider fra Investeringsaktiviteter | -74.757 | -42.002 | -127.874 | 134.554 | 92.499 | 4.51 |
Kapitaludgifter | -0.69 | -1.117 | -0.06 | -0.239 | -0.376 | -0.373 |
Andre Investerings-Cash-Flow-Ting, Total | -74.067 | -40.885 | -127.814 | 134.793 | 92.875 | 4.883 |
Likvider fra Financieringsaktiviteter | 90.515 | 103.03 | 220.727 | 57.622 | 11.34 | 18.332 |
Financiering af Cash-Flow-Ting | 0 | |||||
Udstedelse (Pensionering) af Aktier, Netto | 70.941 | 83.115 | 51.803 | 27.068 | 22.623 | 19.048 |
Udstedelse (Pensionering) af Gæld, Netto | 19.574 | 19.915 | 168.924 | 30.554 | -11.283 | -0.716 |
Netto Ændring i Likviditet | -78.34 | -17.546 | 11.674 | 58.131 | 0.415 | -25.431 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -18.346 | -8.629 | -26.831 | -59.084 | -17.91 |
Cash From Operating Activities | -21.518 | -54.724 | -28.465 | -48.273 | -19.11 |
Cash From Operating Activities | 0.11 | 0.225 | 0.313 | 0.391 | 0.144 |
Non-Cash Items | 1.934 | 7.274 | 10.476 | 18.609 | 3.99 |
Cash Interest Paid | 0.975 | 5.865 | 7.664 | 13.144 | 1.181 |
Changes in Working Capital | -5.216 | -53.594 | -12.423 | -8.189 | -5.334 |
Cash From Investing Activities | 19.738 | 19.621 | 19.627 | 4.51 | -15.196 |
Capital Expenditures | -0.262 | -0.379 | -0.373 | -0.373 | -0.036 |
Other Investing Cash Flow Items, Total | 20 | 20 | 20 | 4.883 | -15.16 |
Cash From Financing Activities | -0.394 | 4.603 | 14.039 | 18.332 | 3.097 |
Issuance (Retirement) of Stock, Net | 0.003 | 5 | 14.436 | 19.048 | 3.097 |
Issuance (Retirement) of Debt, Net | -0.397 | -0.397 | -0.397 | -0.716 | 0 |
Net Change in Cash | -2.174 | -30.5 | 5.201 | -25.431 | -31.209 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
AIGH Capital Management, LLC. | Private Equity | 6.9977 | 3887172 | 0 | 2022-09-30 | MED |
Dugaboy Investment Trust | Corporation | 6.9671 | 3870197 | 978000 | 2022-12-31 | LOW |
Lytton (Laurence W) | Individual Investor | 5.7796 | 3210552 | 3210552 | 2022-05-09 | |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.9148 | 2174625 | 154939 | 2022-09-30 | LOW |
Omega Fund Management, LLC | Investment Advisor | 3.5486 | 1971241 | 0 | 2022-09-30 | LOW |
General American Investors Company, Inc. | Investment Advisor | 3.4494 | 1916099 | 163629 | 2022-09-30 | LOW |
Medical Strategy GmbH | Investment Advisor | 3.2706 | 1816780 | 0 | 2022-09-30 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 3.1216 | 1734037 | 0 | 2022-09-30 | LOW |
Bruce & Company, Inc. | Investment Advisor | 2.8035 | 1557312 | 0 | 2022-09-30 | LOW |
Loh (Evan) | Individual Investor | 2.1751 | 1208238 | -70739 | 2022-12-21 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.1097 | 1171910 | 334401 | 2022-09-30 | LOW |
Abingworth Management Limited | Venture Capital | 1.8742 | 1041131 | 0 | 2022-09-30 | LOW |
Worth Venture Partners, LLC | Investment Advisor/Hedge Fund | 1.7456 | 969698 | 0 | 2022-09-30 | MED |
Two Sigma Investments, LP | Hedge Fund | 1.3409 | 744866 | 491611 | 2022-09-30 | HIGH |
Bigham (Michael F) | Individual Investor | 1.1934 | 662937 | -22125 | 2022-12-21 | LOW |
Woodrow (Adam) | Individual Investor | 1.1724 | 651284 | 5677 | 2022-12-21 | LOW |
1492 Capital Management, LLC | Investment Advisor/Hedge Fund | 0.902 | 501050 | 11674 | 2022-09-30 | MED |
J. Goldman & Co., L.P. | Hedge Fund | 0.8263 | 459000 | 438647 | 2022-09-30 | |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7956 | 441935 | 5616 | 2022-09-30 | LOW |
Haskel William M | Individual Investor | 0.7341 | 407800 | -30001 | 2022-12-21 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com GroupHandlende
Månedlkige, aktive klienter
Månedlig investeringsvolumen
Hævet hver måned
Handelslommeregner
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Paratek Pharma Company profile
Om Paratek Pharma
Paratek Pharmaceuticals, Inc. er en biofarmaceutisk virksomhed i den kommercielle fase. Selskabet er fokuseret på udvikling og markedsføring af nye livreddende behandlinger mod livstruende sygdomme. Selskabets produkt omfatter NUZYRA (omadacyclin) er et oralt og intravenøst antibiotikum til behandling af bakteriel lungebetændelse og akutte infektioner i hud og hudstruktur forårsaget af modtagelige patogener. Selskabets andre produkter omfatter SEYSARA, som er et oralt behandlingsmiddel til behandling af moderat til svær acne vulgaris.
Industry: | Pharmaceuticals (NEC) |
75 Park Plaza
4Th Floor
BOSTON
MASSACHUSETTS 02116
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com